Health/Biotechnology
Rydex Biotechnology Fund
Last updated: 2026-03-13
The Verdict
Rydex Biotechnology Fund charges an expense ratio of 1.39%. On a $100,000 portfolio, that's $1,390 per year in fees. Supreme.PM's decoded model provides similar exposure at a fraction of the cost, potentially saving $1,140 per year.
Expense Ratio
1.39%
Star Rating
2/ 5
Market Beta
0.92
Supreme.PM Cost
0.25%
Annual platform fee
Fee Analysis
Rydex Biotechnology Fund charges 1.39% annually. Supreme.PM offers equivalent exposure for 0.25%, a savings of 1.14 percentage points.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Health/Biotechnology Category
Browse all Health/Biotechnology funds
Health/Biotechnology Rankings
Top-rated Health/Biotechnology funds
Our Methodology
How we decode fund strategies
Fidelity Advisor Health Care Fund
3-star rated
Virtus KAR Health Sciences Fund
2-star rated
Fidelity Select Health Care Portfolio
3-star rated
DWS Health and Wellness Fund
3-star rated
PGIM Jennison Health Sciences Fund
4-star rated
Frequently Asked Questions
What is the expense ratio of Rydex Biotechnology Fund?
Rydex Biotechnology Fund has an expense ratio of 1.39%. Supreme.PM's decoded model provides similar exposure at a significantly lower cost.
How does Supreme.PM replicate Rydex Biotechnology Fund?
Supreme.PM uses AI to analyze the fund's holdings and trading patterns, creating a decoded model that tracks the fund's performance.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.